Drugs / ST-2427
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04475198 | Mar → Aug 2021 | — | SiteOne Therapeutics, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ST-2427 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04475198 ↗ |
| Route | Intravenous | “5 mg ST-2427 (n=4) or placebo (n=2) administered once over a 60-minute intravenous (IV) infusion.” NCT04475198 ↗ |